{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:58:46Z","timestamp":1793134726328,"version":"4.5.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The SENTRY Antimicrobial Surveillance Program was established in 1997 and presently encompasses more than 750 000 bacterial isolates from over 400 medical centers worldwide. Among these pathogens, enterococci represents a prominent cause of bloodstream (BSIs), intra-abdominal (IAIs), skin and skin structure, and urinary tract infections (UTIs). In the present study, we reviewed geographic and temporal trends in Enterococcus species and resistant phenotypes identified throughout the SENTRY Program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From 1997 to 2016, a total of 49 491 clinically significant enterococci isolates (15 species) were submitted from 298 medical centers representing the Asia-Pacific (APAC), European, Latin American (LATAM), and North American (NA) regions. Bacteria were identified by standard algorithms and matrix-assisted laser desorption ionization\u2013time of flight mass spectrometry. Susceptibility (S) testing was performed by reference broth microdilution methods and interpreted using Clinical and Laboratory Standards Institute\/US Food and Drug Administration and European Committee on Antimicrobial Susceptibility Testing criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most common Enterococcus species in all 4 regions were Enterococcus faecalis (64.7%) and E. faecium (EFM; 29.0%). Enterococci accounted for 10.7% of BSIs in NA and was most prominent as a cause of IAIs (24.0%) in APAC and of UTIs (19.8%) in LATAM. A steady decrease in the susceptibility to ampicillin and vancomycin was observed in all regions over the 20-year interval. Vancomycin-resistant enterococci (VRE) accounted for more than 8% of enterococcal isolates in all regions and was most common in NA (21.6%). Among the 7615 VRE isolates detected, 89.1% were the VanA phenotype (91.0% EFM) and 10.9% were VanB. Several newer antimicrobial agents demonstrated promising activity against VRE, including daptomycin (99.6\u2013100.0% S), linezolid (98.0%\u201399.6% S), oritavancin (92.2%\u201398.3% S), tedizolid (99.5%\u2013100.0% S), and tigecycline (99.4%\u2013100.0% S).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Enterococci remained a prominent gram-positive pathogen in the SENTRY Program from 1997 through 2016. The overall frequency of VRE was 15.4% and increased over time in all monitored regions. Newly released agents with novel mechanisms of action show promising activity against VRE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofy344","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T02:55:05Z","timestamp":1552704905000},"page":"S54-S62","source":"Crossref","is-referenced-by-count":116,"title":["Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997\u20132016"],"prefix":"10.1093","volume":"6","author":[{"given":"Michael A","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cormican","sequence":"additional","affiliation":[{"name":"National University of Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"2020081004064905200_CIT0001","author":"ECDC","year":"2013"},{"key":"2020081004064905200_CIT0002","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004064905200_CIT0003","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"2020081004064905200_CIT0004","author":"CDC","year":"2013"},{"key":"2020081004064905200_CIT0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/ice.2016.254","article-title":"Incidence and outcomes associated with infections caused by vancomycin-resistant Enterococci in the United States: systematic literature review and meta-analysis","volume":"38","author":"Chiang","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004064905200_CIT0006","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? A review of novel antibiotics for gram-positive bacteria","volume":"23","author":"Abbas","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2020081004064905200_CIT0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/523588","article-title":"Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia","volume":"46","author":"Erlandson","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020081004064905200_CIT0008","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.02943-14","article-title":"Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci","volume":"58","author":"Hayakawa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004064905200_CIT0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1055\/s-2007-996410","article-title":"Optimizing therapy for vancomycin-resistant enterococci (VRE)","volume":"28","author":"Linden","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"2020081004064905200_CIT0010","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/jac\/dkw319","article-title":"Longitudinal (2001\u201314) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010\u201313) analysis of oritavancin in vitro potency","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0011","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1093\/cid\/civ523","article-title":"Evolving resistance among gram-positive pathogens","volume":"61","author":"Munita","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081004064905200_CIT0012","doi-asserted-by":"crossref","first-page":"e00609","DOI":"10.1128\/AAC.00609-17","article-title":"Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important gram-positive cocci in the United States rom the LEADER Surveillance Program (2011 to 2015)","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004064905200_CIT0013","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijid.2014.02.012","article-title":"Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study","volume":"26","author":"Billington","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2020081004064905200_CIT0014","first-page":"E236","article-title":"Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Programme annual report, 2014","volume":"40","author":"Coombs","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"key":"2020081004064905200_CIT0015","first-page":"620","article-title":"Emerging vancomycin resistance in enterococci in India","volume":"49","author":"Ghoshal","year":"2006","journal-title":"Indian J Pathol Microbiol"},{"key":"2020081004064905200_CIT0016","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/jac\/dkt054","article-title":"Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999\u20132009","volume":"68","author":"McCracken","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0017","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/670998","article-title":"Prevalence of colonization and infection with methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus and of Clostridium difficile infection in Canadian hospitals","volume":"34","author":"Simor","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004064905200_CIT0018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.diagmicrobio.2012.09.006","article-title":"Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China","volume":"74","author":"Sun","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0019","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.diagmicrobio.2013.01.004","article-title":"High rates of multidrug resistance in Enterococcus faecalis and E. faecium isolated from inpatients and outpatients in Taiwan","volume":"75","author":"Wang","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3201\/1106.041204","article-title":"Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex","volume":"11","author":"Willems","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"2020081004064905200_CIT0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/CMR.3.1.46","article-title":"The life and times of the Enterococcus","volume":"3","author":"Murray","year":"1990","journal-title":"Clin Microbiol Rev"},{"key":"2020081004064905200_CIT0022","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.tim.2017.01.004","article-title":"Multidrug-resistant enterococcal infections: new compounds, novel antimicrobial therapies","volume":"25","author":"van Harten","year":"2017","journal-title":"Trends Microbiol"},{"key":"2020081004064905200_CIT0023","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/jhin.2002.1375","article-title":"Vancomycin-resistant enterococci: 15 years and counting","volume":"53","author":"Chavers","year":"2003","journal-title":"J Hosp Infect"},{"key":"2020081004064905200_CIT0024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diagmicrobio.2006.12.022","article-title":"Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY Antimicrobial Surveillance Program","volume":"58","author":"Deshpande","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-135-3-200108070-00009","article-title":"The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units","volume":"135","author":"Fridkin","year":"2001","journal-title":"Ann Intern Med"},{"key":"2020081004064905200_CIT0026","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3201\/eid1006.020665","article-title":"Reference group choice and antibiotic resistance outcomes","volume":"10","author":"Kaye","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"2020081004064905200_CIT0027","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/jac\/dkh138","article-title":"Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis","volume":"53","author":"Oprea","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0028","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1086\/382086","article-title":"Beta-lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci","volume":"189","author":"Rice","year":"2004","journal-title":"J Infect Dis"},{"key":"2020081004064905200_CIT0029","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/430909","article-title":"Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis","volume":"41","author":"DiazGranados","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020081004064905200_CIT0030","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3201\/eid0909.020383","article-title":"Epidemic and nonepidemic multidrug-resistant Enterococcus faecium","volume":"9","author":"Leavis","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"2020081004064905200_CIT0031","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10096-005-0056-0","article-title":"Spread of ampicillin\/vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals","volume":"24","author":"Klare","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0032","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jinf.2009.01.013","article-title":"Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome","volume":"58","author":"Han","year":"2009","journal-title":"J Infect"},{"key":"2020081004064905200_CIT0033","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1086\/320185","article-title":"Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Low","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020081004064905200_CIT0034","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.06067-11","article-title":"Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009\u20132010","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004064905200_CIT0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0732-8893(03)00012-9","article-title":"Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000)","volume":"46","author":"Mutnick","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0036","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.42.7.1762","article-title":"Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)","volume":"42","author":"Pfaller","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004064905200_CIT0037","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1128\/AAC.01473-15","article-title":"Detection of a new CFR-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: report from the SENTRY Antimicrobial Surveillance Program","volume":"59","author":"Deshpande","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004064905200_CIT0038","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","article-title":"Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002)","volume":"50","author":"Biedenbach","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0039","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0924-8579(02)00204-2","article-title":"Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997\u20132000","volume":"20","author":"Diekema","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004064905200_CIT0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0732-8893(01)00333-9","article-title":"Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program","volume":"42","author":"Jones","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0041","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1128\/JCM.41.8.4004-4005.2003","article-title":"Distribution of fsr among Enterococcus faecalis isolates from the SENTRY Antimicrobial Surveillance Program","volume":"41","author":"Jones","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2020081004064905200_CIT0042","first-page":"10","article-title":"Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"109","author":"Pfaller","year":"2001","journal-title":"Postgrad Med"},{"key":"2020081004064905200_CIT0043","volume-title":"M07Ed11E. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard","author":"CLSI","year":"2018","edition":"11th ed"},{"key":"2020081004064905200_CIT0044","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: 28th Informational Supplement","author":"CLSI. M100Ed28E","year":"2018"},{"key":"2020081004064905200_CIT0045","author":"EUCAST","year":"2018"},{"key":"2020081004064905200_CIT0046","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0732-8893(97)00115-6","article-title":"Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group","volume":"29","author":"Jones","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0047","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020081004064905200_CIT0048","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"2020081004064905200_CIT0049","author":"ECDC","year":"2014"},{"key":"2020081004064905200_CIT0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/46.suppl_2.1","article-title":"Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection","volume":"46","author":"Jones","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0051","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0732-8893(01)00318-2","article-title":"Determining the value of antimicrobial surveillance programs","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0052","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/JCM.40.10.3551-3557.2002","article-title":"Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2020081004064905200_CIT0053","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ajic.2007.01.001","article-title":"Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force","volume":"35","author":"Weber","year":"2007","journal-title":"Am J Infect Control"},{"key":"2020081004064905200_CIT0054","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/cid\/ciy064","article-title":"A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis","volume":"67","author":"Beganovic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020081004064905200_CIT0055","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(00)04376-2","article-title":"Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid","volume":"357","author":"Gonzales","year":"2001","journal-title":"Lancet"},{"key":"2020081004064905200_CIT0056","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","article-title":"Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy","volume":"49","author":"Lewis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004064905200_CIT0057","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2005.05.005","article-title":"Tigecycline activity tested against 26","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0058","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/jac\/dky188","article-title":"Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program","volume":"73","author":"Deshpande","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0059","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/jsfa.8115","article-title":"Characterization of antimicrobial resistance and quinolone resistance factors in high-level ciprofloxacin-resistant Enterococcus faecalis and Enterococcus faecium isolates obtained from fresh produce and fecal samples of patients","volume":"97","author":"Kim","year":"2017","journal-title":"J Sci Food Agric"},{"key":"2020081004064905200_CIT0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/jac\/dkg052","article-title":"Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals","volume":"51","author":"Simonsen","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0061","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/49.1.17","article-title":"The current status of surveillance of resistance to antimicrobial agents: report on a meeting","volume":"49","author":"Hunter","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0062","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0732-8893(96)00099-5","article-title":"The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance","volume":"25","author":"Jones","year":"1996","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004064905200_CIT0063","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/46.suppl_2.53","article-title":"Surveillance studies: how can they help the management of infection","volume":"46","author":"Masterton","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2020081004064905200_CIT0064","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QCO.0000000000000182","article-title":"The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria","volume":"28","author":"Perez","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"2020081004064905200_CIT0065","doi-asserted-by":"crossref","first-page":"e00906","DOI":"10.1128\/AAC.00906-17","article-title":"Monitoring antifungal resistance in a global collection of invasive yeasts and moulds: application of CLSI epidemiological cutoff values and whole genome sequencing analysis for detection of azole resistance in Candida albicans","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/Supplement_1\/S54\/33591193\/ofy344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/Supplement_1\/S54\/33591193\/ofy344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:14:05Z","timestamp":1597047245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/6\/Supplement_1\/S54\/5381627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":65,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2019,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy344","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3]]}}}